Scantox Unveils Gentronix's Rebranding and Expanded Services in Genetic Toxicology

In a significant move within the genetic toxicology sector, Scantox Group has announced that Gentronix, a leading contract research organization acquired in 2024, will now operate under the new name Scantox Manchester. This rebranding represents not just a change of name but also a deeper integration of Gentronix's significant scientific expertise, talent, and valuable client relationships into the Scantox umbrella. This initiative caters to an evolving landscape in the industry, ensuring that the same high level of service continues, but with enhanced capabilities and broader resources.

The rebranding follows a period of substantial investment by Scantox into its genetic toxicology and genomic safety services. This investment surge has enabled the company to increase its Big Blue® transgenic rodent gene mutation assay capacity, thereby responding to an increased demand in the market. Additionally, Scantox has successfully launched an Enhanced Ames Test program. One of the standout achievements is the acquisition of the DuplexSeq™ nonclinical genomic safety business from TwinStrand Biosciences, which sets Scantox apart as the sole provider of DuplexSeq™ Mutagenesis Assays.

By consolidating these resources under one roof, Scantox has positioned itself to offer an integrated suite of services that support clients from early screening stages right through to late-stage regulatory development. This ambitious move showcases Scantox's commitment to leading the way in how mutagenic risk is assessed.

Leadership Insights

The leadership team at Scantox has been pivotal in this transition. Jeanet Løgsted, CEO of Scantox Group, emphasized the unity and strength of the newly structured team in driving future innovations. “This milestone is built on great science and great people,” Løgsted stated. She affirmed that the Manchester team has drastically transformed Scantox’s offerings in genetic toxicology and genomic safety while maintaining the client-focused approach that Gentronix was known for.

The reorganization also sees Matt Tate stepping into the new role of Chief Business Development Officer, while Laura Hinton assumes the position of Site Head at Scantox Manchester. Tate expressed excitement about the innovative direction of the industry, noting that the ability to provide comprehensive genomic safety data across various stages of the product development lifecycle was unprecedented in the contract research organization (CRO) field.

“This is the evolution of how our industry assesses mutagenic risk. Scantox is redefining the future,” said Tate, highlighting that with all the protean services available, clients can now access a continuum of support without having to engage multiple providers. The importance of using the appropriate tools at each stage of development cannot be overstated, and Scantox's new offerings are set to lead the industry standard.

Hinton underscored the strong foundation laid by the team, emphasizing an experienced workforce, a loyal client base, and a proven history of delivering high-quality scientific outcomes. She encourages continued growth and optimization of services, assuring clients that their expectations for quality and service will be met with higher standards moving forward.

About Scantox

Scantox is an integrated preclinical Contract Research Organization (CRO) that supports clients from the exploration phases through IND-enabling nonclinical development. With operations spanning Denmark, Sweden, Austria, and the UK, Scantox combines its strengths in Discovery, Regulatory Toxicology, and Genetic Toxicology to provide coordinated expertise. This strategy enables the creation of high-quality, regulator-ready data while keeping timelines synchronized across various disciplines. Scantox prides itself on its deep knowledge in areas like CNS pharmacology and assessments associated with Göttingen minipigs, alongside its advanced capabilities in genetic toxicology. Founded in 1977, Scantox is owned by Impilo, a leading Nordic healthcare investment company.

This evolution of Gentronix into Scantox Manchester marks a pivotal chapter in its legacy, aiming to not only uphold but to surpass the benchmarks set in the realm of genetic toxicity assessments and client service.